United States Pharmaceuticals

Scholar Rock Holding Corp (SRRK)

Track

Over the past 90 days, Scholar Rock Holding Corp has seen 19 insider transactions, all of which were sales totaling approximately $2.5 million. These activities, involving various directors and officers, were primarily executed as planned or proposed sales. The stock price has remained relatively stable, declining 1.1% during this period.
Ticker: SRRK Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Scholar Rock Holding Corp. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 6 Jul 2026
Value US$3,538,079.20 | Price 260.04 | Shares 9,384
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-06 2026-07-06 PrS Proposed sale
3.4
Mohammed Qatanani

Officer

Officer
9,384
260.04
US$3,538,079 		9,384 260.04 US$3,538,079
2026-07-06 2026-07-01 PlS Planned sale
FLIER JEFFREY S.
Non-Executive Director
87,269 +11.3%
227.02
US$377,937 		87,269 +11.3% 227.02 US$377,937
2026-07-06 2026-07-01 PlS Planned sale
FLIER JEFFREY S.
Non-Executive Director
81,686 +35.2%
431.30
US$2,701,515 		81,686 +35.2% 431.30 US$2,701,515
2026-07-06 2026-07-01 PlS Planned sale
FLIER JEFFREY S.
Non-Executive Director
1,568 -5.1%
53.53
US$83,939 		1,568 -5.1% 53.53 US$83,939
2026-07-06 2026-07-01 PlS Planned sale
3.2
Burow Kristina
Non-Executive Director
948 -0.8%
54.28
US$51,459 		948 -0.8% 54.28 US$51,459
2026-07-06 2026-07-01 PlS Planned sale
3.2
Burow Kristina
Non-Executive Director
2,105 -1.8%
53.49
US$112,605 		2,105 -1.8% 53.49 US$112,605
2026-07-06 2026-07-01 PlS Planned sale
Gilman Michael
Non-Executive Director
43 -0.1%
54.81
US$2,357 		43 -0.1% 54.81 US$2,357
2026-07-06 2026-07-01 PlS Planned sale
Gilman Michael
Non-Executive Director
1,155 -1.9%
54.23
US$62,631 		1,155 -1.9% 54.23 US$62,631
2026-07-06 2026-07-01 PlS Planned sale
Gilman Michael
Non-Executive Director
1,346 -2.2%
53.54
US$72,070 		1,346 -2.2% 53.54 US$72,070
2026-07-06 2026-07-01 PlS Planned sale
1.5
Peng Katie
Non-Executive Director
21 -0.1%
54.96
US$1,154 		21 -0.1% 54.96 US$1,154
2026-07-06 2026-07-01 PlS Planned sale
1.5
Peng Katie
Non-Executive Director
2,437 -6.6%
54.25
US$132,214 		2,437 -6.6% 54.25 US$132,214
2026-07-06 2026-07-01 PlS Planned sale
1.5
Peng Katie
Non-Executive Director
2,988 -7.5%
53.56
US$160,037 		2,988 -7.5% 53.56 US$160,037
2026-07-06 2026-07-01 PlS Planned sale
Reed Joshua
Non-Executive Director
948 -4.6%
54.28
US$51,459 		948 -4.6% 54.28 US$51,459
2026-07-06 2026-07-01 PlS Planned sale
Reed Joshua
Non-Executive Director
2,105 -9.3%
53.50
US$112,609 		2,105 -9.3% 53.50 US$112,609
2026-07-01 2026-07-01 PrS Proposed sale
Joshua Reed

Director

Non-Executive Director
3,053
54.79
US$167,274 		3,053 54.79 US$167,274
2026-07-01 2026-07-01 PrS Proposed sale
Jeffrey S. Flier

Director

Non-Executive Director
3,053
54.79
US$167,274 		3,053 54.79 US$167,274
2026-07-01 2026-07-01 PrS Proposed sale
3.2
Kristina Burow

Director

Non-Executive Director
3,053
54.79
US$167,274 		3,053 54.79 US$167,274
2026-07-01 2026-07-01 PrS Proposed sale
Michael Gilman

Director

Non-Executive Director
2,544
54.79
US$139,385 		2,544 54.79 US$139,385
2026-07-01 2026-07-01 PrS Proposed sale
1.5
Katie Peng

Director

Non-Executive Director
5,446
54.79
US$298,386 		5,446 54.79 US$298,386
2026-04-20 2026-04-16 S Sale
1.2
Woods Keith

Chief Operating Officer

Officer
10,220 -1.6%
49.57
US$506,651 		10,220 -1.6% 49.57 US$506,651
2026-04-20 2026-04-16 S Sale
2.4
Vaishnaw Akshay

President of R&D

Executive Director
12,246 -1.9%
49.57
US$607,089 		12,246 -1.9% 49.57 US$607,089
2026-04-20 2026-04-16 S Sale
2.7
Sinha Vikas

Chief Financial Officer

Officer
10,410 -1.7%
49.57
US$516,071 		10,410 -1.7% 49.57 US$516,071
2026-04-20 2026-04-16 S Sale
3.0
Hallal David

Chief Executive Officer

Executive Director
30,615 -1.8%
49.57
US$1,517,723 		30,615 -1.8% 49.57 US$1,517,723
2026-04-06 2026-04-06 PrS Proposed sale
3.4
Mohammed Qatanani

Officer

Officer
23,408
50.01
US$1,170,634 		23,408 50.01 US$1,170,634
2026-02-25 2026-02-23 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
200 -0.2%
48.48
US$9,696 		200 -0.2% 48.48 US$9,696
2026-02-25 2026-02-23 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
857 -0.9%
47.86
US$41,015 		857 -0.9% 47.86 US$41,015
2026-02-25 2026-02-23 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
7,427 -6.9%
46.94
US$348,640 		7,427 -6.9% 46.94 US$348,640
2026-02-23 2026-02-23 PrS Proposed sale
3.4
Mohammed Qatanani

Officer

Officer
8,484
48.32
US$409,947 		8,484 48.32 US$409,947
2026-02-19 2026-02-17 S Sale
2.9
Marantz Jing L.

CHIEF MEDICAL OFFICER

Officer
4,157 -3.2%
46.53
US$193,418 		4,157 -3.2% 46.53 US$193,418
2026-02-19 2026-02-17 S Sale
3.3
Ho Junlin

GENERAL COUNSEL

Officer
9,580 -3.8%
46.53
US$445,740 		9,580 -3.8% 46.53 US$445,740
2026-02-19 2026-02-17 S Sale
3.2
Parlavecchio Caryn

CHRO

Officer
9,035 -5.1%
46.53
US$420,382 		9,035 -5.1% 46.53 US$420,382
2026-02-19 2026-02-17 S Sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
7,989 -7.0%
46.53
US$371,714 		7,989 -7.0% 46.53 US$371,714
2026-01-23 2026-01-22 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
12,779 -13.0%
46.85
US$598,749 		12,779 -13.0% 46.85 US$598,749
2026-01-23 2026-01-22 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
2,119 -2.1%
45.87
US$97,189 		2,119 -2.1% 45.87 US$97,189
2026-01-22 2026-01-22 PrS Proposed sale
3.4
Mohammed Qatanani

Officer

Officer
14,898
46.05
US$686,053 		14,898 46.05 US$686,053
2026-01-21 2026-01-16 S Sale
2.9
Marantz Jing L.

CHIEF MEDICAL OFFICER

Officer
5,798 -5.7%
44.48
US$257,882 		5,798 -5.7% 44.48 US$257,882
2026-01-21 2026-01-16 S Sale
3.3
Ho Junlin

GENERAL COUNSEL

Officer
8,016 -3.6%
44.48
US$356,533 		8,016 -3.6% 44.48 US$356,533
2026-01-21 2026-01-16 S Sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
8,406 -7.7%
44.48
US$373,880 		8,406 -7.7% 44.48 US$373,880
2026-01-21 2026-01-16 S Sale
3.2
Parlavecchio Caryn

CHRO

Officer
6,600 -4.2%
44.48
US$293,553 		6,600 -4.2% 44.48 US$293,553
2026-01-16 2026-01-14 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
13,112 -10.7%
45.20
US$592,611 		13,112 -10.7% 45.20 US$592,611
2026-01-15 2026-01-13 S Sale
2.7
Sinha Vikas

Chief Financial Officer

Officer
16,755 -2.8%
42.70
US$715,438 		16,755 -2.8% 42.70 US$715,438
2026-01-15 2026-01-13 S Sale
3.0
Hallal David

Chief Executive Officer

Executive Director
57,450 -3.6%
42.70
US$2,453,115 		57,450 -3.6% 42.70 US$2,453,115
2026-01-15 2026-01-13 S Sale
1.2
Woods Keith

Chief Operating Officer

Officer
16,746 -2.8%
42.70
US$715,054 		16,746 -2.8% 42.70 US$715,054
2026-01-15 2026-01-13 S Sale
2.4
Vaishnaw Akshay

President of R&D

Executive Director
20,438 -3.3%
42.70
US$872,703 		20,438 -3.3% 42.70 US$872,703
2025-12-18 2025-12-16 S Sale
1.5
Peng Katie
Non-Executive Director
280 -0.8%
44.63
US$12,498 		280 -0.8% 44.63 US$12,498
2025-12-18 2025-12-16 S Sale
1.5
Peng Katie
Non-Executive Director
726 -2.1%
43.88
US$31,854 		726 -2.1% 43.88 US$31,854
2025-12-16 2025-12-16 PrS Proposed sale
1.5
Katie Peng

Director

Non-Executive Director
1,006
45.24
US$45,511 		1,006 45.24 US$45,511
2025-12-05 2025-12-04 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
136,462 -55.6%
45.21
US$6,169,788 		136,462 -55.6% 45.21 US$6,169,788
2025-12-04 2025-12-04 PrS Proposed sale
3.4
Mohammed Qatanani

Officer

Officer
149,574
43.01
US$6,433,178 		149,574 43.01 US$6,433,178
2025-12-16 2025-10-07 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
4,403 +0.8%
40.97
US$180,391 		4,403 +0.8% 40.97 US$180,391
2025-12-16 2025-10-07 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
12,400 +2.4%
40.18
US$498,232 		12,400 +2.4% 40.18 US$498,232
2025-12-16 2025-10-07 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
12,796 +2.6%
39.31
US$503,011 		12,796 +2.6% 39.31 US$503,011
2025-10-07 2025-10-06 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
13,748 +2.8%
39.52
US$543,321 		13,748 +2.8% 39.52 US$543,321
2025-10-07 2025-10-06 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
80,863 +19.9%
38.68
US$3,127,781 		80,863 +19.9% 38.68 US$3,127,781
2025-10-07 2025-10-06 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
18,414 +4.8%
37.89
US$697,706 		18,414 +4.8% 37.89 US$697,706
2025-10-07 2025-10-03 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
319,700 +472.1%
37.42
US$11,963,174 		319,700 +472.1% 37.42 US$11,963,174
2025-10-07 2025-10-03 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
56,703 +515.0%
36.74
US$2,083,268 		56,703 +515.0% 36.74 US$2,083,268
2025-10-07 2025-10-03 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
11,011 +inf%
35.61
US$392,102 		11,011 +inf% 35.61 US$392,102
2025-09-24 2025-09-22 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
3,353 -3.0%
30.67
US$102,846 		3,353 -3.0% 30.67 US$102,846
2025-09-22 2025-09-22 PrS Proposed sale
3.4
Mohammed Qatanani

Officer

Officer
3,353
30.67
US$102,846 		3,353 30.67 US$102,846
2025-09-17 2025-09-16 PlS Planned sale
1.5
Peng Katie
Non-Executive Director
76 -0.2%
33.20
US$2,523 		76 -0.2% 33.20 US$2,523
2025-09-17 2025-09-16 PlS Planned sale
1.5
Peng Katie
Non-Executive Director
930 -2.7%
32.48
US$30,203 		930 -2.7% 32.48 US$30,203
2025-09-17 2025-09-16 S Sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
3,178 -2.8%
33.52
US$106,527 		3,178 -2.8% 33.52 US$106,527
2025-09-16 2025-09-16 PrS Proposed sale
1.5
Katie Peng

Director

Non-Executive Director
1,006
32.53
US$32,726 		1,006 32.53 US$32,726
2025-08-19 2025-08-18 S Sale
3.2
Parlavecchio Caryn

CHRO

Officer
2,178 -1.4%
31.17
US$67,880 		2,178 -1.4% 31.17 US$67,880
2025-07-18 2025-07-16 PlS Planned sale
FLIER JEFFREY S.
Non-Executive Director
11,136 -100.0%
40.02
US$445,688 		11,136 -100.0% 40.02 US$445,688
2025-07-10 2025-07-08 PlS Planned sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
24,066 -17.2%
34.44
US$828,898 		24,066 -17.2% 34.44 US$828,898
2025-07-08 2025-07-08 PrS Proposed sale
3.4
Mohammed Qatanani

Officer

Officer
24,066
35.48
US$853,862 		24,066 35.48 US$853,862
2025-06-25 2025-06-23 PlS Planned sale
FLIER JEFFREY S.
Non-Executive Director
11,136 -50.0%
33.21
US$369,818 		11,136 -50.0% 33.21 US$369,818
2025-06-25 2025-06-23 PlS Planned sale
FLIER JEFFREY S.
Non-Executive Director
2,766 -10.3%
32.74
US$90,547 		2,766 -10.3% 32.74 US$90,547
2025-06-25 2025-06-23 PlS Planned sale
FLIER JEFFREY S.
Non-Executive Director
17,550 -39.5%
32.16
US$564,357 		17,550 -39.5% 32.16 US$564,357
2025-06-17 2025-06-16 S Sale
3.2
Parlavecchio Caryn

CHRO

Officer
6,186 -3.8%
32.00
US$197,961 		6,186 -3.8% 32.00 US$197,961
2025-06-17 2025-06-16 S Sale
3.4
Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Officer
3,668 -2.6%
32.00
US$117,381 		3,668 -2.6% 32.00 US$117,381
2025-06-17 2025-06-16 PlS Planned sale
1.5
Peng Katie
Non-Executive Director
54 -0.2%
32.53
US$1,757 		54 -0.2% 32.53 US$1,757
2025-06-17 2025-06-16 PlS Planned sale
1.5
Peng Katie
Non-Executive Director
2,977 -7.8%
31.96
US$95,132 		2,977 -7.8% 31.96 US$95,132
Explore more

More insider trading research around Scholar Rock Holding Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America